Alexion Pharmaceuticals
edit

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. for the production of Soliris.

Milestones
edit

Alexion Pharmaceuticals added Vikas Sinha as CFO.

Posted 1/31/11 at 8:59pm
Alexion Pharmaceuticals added Leonard Bell as CEO.

Posted 1/31/11 at 8:59pm
Went public with stock symbol NASDAQ:ALXN.

Posted 1/31/11 at 9:00pm
Alexion Pharmaceuticals acquired Enobia Pharma. (12/29/11)

Posted 12/29/11 at 7:47pm via yahoo.com
Alexion Pharmaceuticals acquired Taligen Therapeutics for $111M. (1/31/11)

Posted 1/31/11 at 8:59pm via masshightech.com
Alexion Pharmaceuticals — has won priority review from the U.S. Food and Drug Administration (6/1/11)

Posted 6/2/11 at 6:35am via masshightech.com
Alexion Pharmaceuticals — has won approval from its board of directors for a two-for-one stock split, which if approved would double the number of issued common stock shares from 145 million to 290 million (3/30/11)

Posted 3/30/11 at 5:22am via masshightech.com
Alexion Pharmaceuticals — acquired patents and assets for a possible therapy for a ultra-rare genetic disorder for $3 million in cash from Germany-based Orphatec Pharmaceuticals GmbH (2/10/11)

Posted 2/10/11 at 6:11am via masshightech.com